Bayer's Recovery Story Gains Traction as Analyst Targets Climb and Legal Calendar Firms Up

Bayer returns to Q2 profit, prompting Goldman, UBS, and DZ Bank to raise price targets; crop science and debt outlook fuel optimism.

The investment case for Bayer has shifted noticeably over the past week, with three major financial institutions raising their price targets within hours of each other on Wednesday — a rare convergence that signals a broader reassessment of the Leverkusen-based conglomerate's prospects.

Goldman Sachs led the charge, lifting its target from €62.50 to €63.50 while maintaining a "Buy" rating. Analyst James Quigley pointed to the strong operational performance in the agricultural division as the primary catalyst. UBS went a step further, upgrading the stock from "Neutral" to "Buy" and raising its target from €52.00 to €62.00. The DZ Bank also joined the chorus, increasing its fair value estimate from €54.00 to €60.00 with a buy recommendation, citing the company's reduced net debt.

JPMorgan, while keeping its target at €50 with an "Overweight" rating, echoed the sentiment, noting that strong results and a confirmed outlook were nudging expectations for the full year upward.

A Quarter That Changed the Narrative

The fundamental trigger for this wave of optimism came last Thursday, when Bayer reported a return to profitability for the second quarter. The group posted a net profit of €219 million, a sharp turnaround from the €199 million loss recorded in the same period last year. Adjusted EBITDA rose 1.9 percent to €2.144 billion, beating market consensus. Revenue grew 2.2 percent to €10.872 billion, while core earnings per share fell 16.7 percent to €0.95, weighed down by higher litigation-related payments that pushed free cash flow into negative territory.

Since the earnings release, the stock has gained 1.1 percent. By Friday's close, shares stood at €49.90, up 1.05 percent on the day and 3.14 percent for the week. The stock has now advanced 34.83 percent since the start of the year, though it remains 7.35 percent below its 52-week high of €53.86 reached in early July.

Crop Science Carries the Load

The agricultural division delivered the strongest operational momentum. Revenue grew 3.5 percent on a currency- and portfolio-adjusted basis, propelled by a 16.9 percent increase in soybean seed sales and a remarkable 69.2 percent surge in cottonseed following the reauthorization of the Dicamba label in the United States.

The pharma business painted a more mixed picture. Growth drivers Nubeqa and Kerendia expanded by 64 percent and 83 percent respectively, offsetting double-digit revenue declines for the blood thinner Xarelto, which has lost patent protection. The segment grew a modest 0.8 percent overall, with EBITDA slipping slightly. The transition from legacy products to newer treatments appears to be holding up without dragging down total revenue — a key reassurance for investors.

Debt Outlook Improves

Management also delivered encouraging news on the balance sheet front. The company lowered its year-end net financial debt forecast to €29–30 billion, down from the previous €32–33 billion range. This improvement is closely tied to a July 10 transaction in which Bayer sold a minority stake in a newly formed entity housing its reversible long-term contraception business to investment firm Apollo, securing €3.0 billion in equity. Bayer retains majority ownership and full operational control, with the deal expected to close in the third quarter of 2026.

At current exchange rates, the company projects full-year revenue of €44.7–46.7 billion and core earnings per share of €4.20–4.70. CEO Bill Anderson said the company is fully on track to meet its annual guidance, adding that the strategy to contain glyphosate litigation rests on a solid foundation, with key milestones still ahead.

Legal Calendar Takes Shape

Those milestones now have a firmer date. A Missouri court has postponed the final approval hearing for the $7.25 billion Roundup class-action settlement from August 19 to September 14, 2026. The additional time will allow the parties to process withdrawal requests from opt-outs, the number of which increased following a favorable Supreme Court ruling for Bayer in the "Durnell" case. That late-June decision affirmed that federal EPA labeling requirements take precedence over state-level warning mandates — a precedent that could bolster Bayer's defense in future glyphosate cases.

The stock has risen 3.1 percent since the postponement was announced just over a week ago. The settlement, if approved, provides for tiered and capped payments of up to $7.25 billion over a maximum of 21 years.

What's Next

Investors now have two key dates on the calendar: the September 14 hearing on the glyphosate settlement and the third-quarter earnings report due November 3. Both events will test whether the improving trajectory in operations and legal risk can be sustained — or whether fresh uncertainties will temper the recently brighter analyst mood.